# Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

> **NCT01997411** · PHASE2,PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 48 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Nasal Glucagon
- **DRUG:** Intramuscular Glucagon

## Key facts

- **NCT ID:** NCT01997411
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01997411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01997411, "Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01997411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*